Advertisement

The Role of PET/CT in Prostate Cancer Management

  • Benjamin Taylor
  • Anna Paschali
  • Vineet Pant
  • Ishita B. Sen
  • Gary CookEmail author
Chapter
Part of the Clinicians’ Guides to Radionuclide Hybrid Imaging book series (CGRHI)

Abstract

PET/CT had a number of potential roles in prostate cancer management strategies, and each of these will be considered in turn:
  1. 1.

    Diagnosis

     
  2. 2.

    Staging at diagnosis

     
  3. 3.

    Restaging at relapse

     
  4. 4.

    Monitoring treatment response

     
  5. 5.

    Prognostication

     
  6. 6.

    Radiotherapy planning

     

References

  1. 1.
    Gambhir SS, Czernin J, Schwimmer J, Silverman DH, Coleman RE, Phelps ME. A tabulated summary of the FDG PET literature. J Nucl Med. 2001;42:1S–93S.PubMedGoogle Scholar
  2. 2.
    McCarthy M, Siew T, Campbell A, et al. [18]F-Fluoromethylcholine (FCH) PET imaging in patients with castration-resistant prostate cancer: prospective comparison with standard imaging. Eur J Nucl Med Mol Imaging. 2011;38:14–22.CrossRefPubMedGoogle Scholar
  3. 3.
    Kurhanewicz J, Vigneron DB, Hricak H, Narayan P, Carroll P, Nelson SJ. Three-dimensional H-1 MR spectroscopic imaging of the in situ human prostate with high (0.23–0.7 cm3) spatial resolution. Radiology. 1996;198:795–805.CrossRefPubMedGoogle Scholar
  4. 4.
    Mease RC, Foss CA, Pomper MG. PET imaging in prostate cancer: focus on prostate-specific membrane antigen. Curr Top Med Chem. 2013;13:951–62.CrossRefPubMedPubMedCentralGoogle Scholar
  5. 5.
    Rajinikanth A, Manoharan M, Soloway CT, Civantos FJ, Soloway MS. Trends in Gleason score: concordance between biopsy and prostatectomy over 15 years. Urology. 2008;72:177–82.CrossRefPubMedGoogle Scholar
  6. 6.
    Schmid DT, John H, Zweifel R, et al. Fluorocholine PET/CT in patients with prostate cancer: initial experience. Radiology. 2005;235:623–8.CrossRefPubMedGoogle Scholar
  7. 7.
    Li X, Liu Q, Wang M, et al. C-11 choline PET/CT imaging for differentiating malignant from benign prostate lesions. Clin Nucl Med. 2008;33:671–6.CrossRefPubMedGoogle Scholar
  8. 8.
    Beheshti M, Imamovic L, Broinger G, et al. 18F choline PET/CT in the preoperative staging of prostate cancer in patients with intermediate or high risk of extracapsular disease: a prospective study of 130 patients. Radiology. 2010;254:925–33.CrossRefPubMedGoogle Scholar
  9. 9.
    Wetter A, Lipponer C, Nensa F, et al. Simultaneous 18F choline positron emission tomography/magnetic resonance imaging of the prostate: initial results. Investig Radiol. 2013;48(5):256–62.CrossRefGoogle Scholar
  10. 10.
    Contractor K, Challapalli A, Barwick T, et al. Use of [11C]choline PET-CT as a noninvasive method for detecting pelvic lymph node status from prostate cancer and relationship with choline kinase expression. Clin Cancer Res. 2011;17:7673–83.CrossRefPubMedGoogle Scholar
  11. 11.
    Schiavina R, Scattoni V, Castellucci P, et al. 11C-choline positron emission tomography/computerized tomography for preoperative lymph-node staging in intermediate-risk and high-risk prostate cancer: comparison with clinical staging nomograms. Eur Urol. 2008;54:392–401.CrossRefPubMedGoogle Scholar
  12. 12.
    Husarik DB, Miralbell R, Dubs M, et al. Evaluation of [(18)F]-choline PET/CT for staging and restaging of prostate cancer. Eur J Nucl Med Mol Imaging. 2008;35:253–63.CrossRefPubMedGoogle Scholar
  13. 13.
    Picchio M, Spinapolice EG, Fallanca F, et al. [11C]Choline PET/CT detection of bone metastases in patients with PSA progression after primary treatment for prostate cancer: comparison with bone scintigraphy. Eur J Nucl Med Mol Imaging. 2012;39:13–26.CrossRefPubMedGoogle Scholar
  14. 14.
    Beheshti M, Vali R, Waldenberger P, et al. Detection of bone metastases in patients with prostate cancer by 18F fluorocholinea and 18F fluoride PET-CT: a comparative study. Eur J Nucl Med Mol Imaging. 2008;35:1766–74.CrossRefPubMedGoogle Scholar
  15. 15.
    Leventis AK, Shariat SF, Slawin KM. Local recurrence after radical prostatectomy: correlation of US features with prostatic fossa biopsy findings. Radiology. 2001;219:432–9.CrossRefPubMedGoogle Scholar
  16. 16.
    Scattoni V, Roscigno M, Raber M, et al. Multiple vesico-urethral biopsies following radical prostatectomy: the predictive roles of TRUS, DRE, PSA and the pathological stage. Eur Urol. 2003;44:407–14.CrossRefPubMedGoogle Scholar
  17. 17.
    Older RA, Lippert MC, Gay SB, Omary RA, Hillman BJ. Computed tomography appearance of the prostatic fossa following radical prostatectomy. Acad Radiol. 1995;2:470–4.CrossRefPubMedGoogle Scholar
  18. 18.
    Evangelista L, Zattoni F, Guttilla A, Saladini G, Colletti PM, Rubello D. Choline PET or PET/CT and biochemical relapse of prostate cancer: a systematic review and meta-analysis. Clin Nucl Med. 2013;38(5):305–14.CrossRefPubMedGoogle Scholar
  19. 19.
    Beauregard JM, Williams SG, Degrado TR, Roselt P, Hicks RJ. Pilot comparison of F-fluorocholine and F-fluorodeoxyglucose PET/CT with conventional imaging in prostate cancer. J Med Imaging Radiat Oncol. 2010;54:325–32.CrossRefPubMedGoogle Scholar
  20. 20.
    Beheshti M, Vali R, Waldenberger P, et al. The use of F-18 choline PET in the assessment of bone metastases in prostate cancer: correlation with morphological changes on CT. Mol Imaging Biol. 2009;11:446–54.CrossRefPubMedGoogle Scholar
  21. 21.
    Cimitan M, Bortolus R, Morassut S, et al. [18F]fluorocholine PET/CT imaging for the detection of recurrent prostate cancer at PSA relapse: experience in 100 consecutive patients. Eur J Nucl Med Mol Imaging. 2006;33:1387–98.CrossRefPubMedGoogle Scholar
  22. 22.
    Heinisch M, Dirisamer A, Loidl W, et al. Positron emission tomography/computed tomography with F-18-fluorocholine for restaging of prostate cancer patients: meaningful at PSA < 5 ng/ml? Mol Imaging Biol. 2006;8:43–8.CrossRefPubMedGoogle Scholar
  23. 23.
    Vees H, Buchegger F, Albrecht S, et al. 18F-choline and/or 11C-acetate positron emission tomography: detection of residual or progressive subclinical disease at very low prostate-specific antigen values (<1 ng/mL) after radical prostatectomy. BJU Int. 2007;99:1415–20.CrossRefPubMedGoogle Scholar
  24. 24.
    Pelosi E, Arena V, Skanjeti A, et al. Role of whole-body 18F-choline PET/CT in disease detection in patients with biochemical relapse after radical treatment for prostate cancer. Radiol Med. 2008;113:895–904.CrossRefPubMedGoogle Scholar
  25. 25.
    Detti B, Scoccianti S, Franceschini D, et al. Predictive factors of [18F]-Choline PET/CT in 170 patients with increasing PSA after primary radical treatment. J Cancer Res Clin Oncol. 2013;139:521–8.CrossRefPubMedGoogle Scholar
  26. 26.
    Castellucci P, Jadvar H. PET/CT in prostate cancer: non-choline radiopharmaceuticals. Q J Nucl Med Mol Imaging. 2012;56:367–74.PubMedPubMedCentralGoogle Scholar
  27. 27.
    Afshar-Oromieh A, Zechmann CM, Malcher A, et al. Comparison of PET imaging with a Ga-68-labelled PSMA ligand and F-18-choline-based PET/CT for the diagnosis of recurrent prostate cancer. Eur J Nucl Med Mol Imaging. 2014;41:11–20.CrossRefPubMedGoogle Scholar
  28. 28.
    Nanni C, Schiavina R, Boschi S, et al. Comparison of 18F-FACBC and 11C-choline PET/CT in patients with radically treated prostate cancer and biochemical relapse: preliminary results. Eur J Nucl Med Mol Imaging. 2013;40:S11–7.CrossRefPubMedGoogle Scholar
  29. 29.
    Scher HI, Halabi S, Tannock I, et al. Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group. J Clin Oncol. 2008;26:1148–59.CrossRefPubMedPubMedCentralGoogle Scholar
  30. 30.
    Schwarzenbock S, Sachs D, Souvatzoglou M, et al. [[11C]choline as a pharmacodynamic marker for docetaxel therapy]. Nuklearmedizin. 2013;52(4):141–7.CrossRefPubMedGoogle Scholar
  31. 31.
    Oyama N, Ponde DE, Dence C, Kim J, Tai YC, Welch MJ. Monitoring of therapy in androgen-dependent prostate tumor model by measuring tumor proliferation. J Nucl Med. 2004;45:519–25.PubMedGoogle Scholar
  32. 32.
    Breeuwsma AJ, Rybalov M, Leliveld AM, Pruim J, de Jong IJ. Correlation of [11C]choline PET-CT with time to treatment and disease-specific survival in men with recurrent prostate cancer after radical prostatectomy. Q J Nucl Med Mol Imaging. 2012;56(5):440–6.PubMedGoogle Scholar
  33. 33.
    Reske SN, Moritz S, Kull T. [11C]Choline-PET/CT for outcome prediction of salvage radiotherapy of local relapsing prostate carcinoma. Q J Nucl Med Mol Imaging. 2012;56(5):430–9.PubMedGoogle Scholar
  34. 34.
    Pinkawa M, Piroth MD, Holy R, et al. Dose-escalation using intensity-modulated radiotherapy for prostate cancer—evaluation of quality of life with and without (18)F-choline PET-CT detected simultaneous integrated boost. Radiat Oncol. 2012;7:14.CrossRefPubMedPubMedCentralGoogle Scholar
  35. 35.
    Vees H, Steiner C, Dipasquale G, et al. Target volume definition in high-risk prostate cancer patients using sentinel node SPECT/CT and 18 F-choline PET/CT. Radiat Oncol. 2012;7:134.CrossRefPubMedPubMedCentralGoogle Scholar

Copyright information

© Springer International Publishing AG 2017

Authors and Affiliations

  • Benjamin Taylor
    • 1
  • Anna Paschali
    • 2
  • Vineet Pant
    • 3
  • Ishita B. Sen
    • 3
  • Gary Cook
    • 1
    • 4
    Email author
  1. 1.Department of Cancer Imaging, Division of Imaging Sciences and Biomedical EngineeringKing’s College LondonLondonUK
  2. 2.Clinical PET Centre, Division of Imaging Sciences and Biomedical EngineeringKing’s College LondonLondonUK
  3. 3.Nuclear Medicine Fortis Memorial Research InstituteGurgaonIndia
  4. 4.Guy’s and St Thomas’ Hospitals NHS Foundation Trust, NIHR Biomedical Research CentreLondonUK

Personalised recommendations